AbbVie Inc. · NYSE:ABBV

AbbVie — Investor Presentation

22 slides from AbbVie's investor presentation

  1. Slide 1: AbbVie: Who we are

    AbbVie: Who we are abobvie

  2. Slide 2: At AbbVie, we strive to make a remarkable impact on the lives of patients

    At AbbVie, we strive to make a remarkable impact on the lives of patients. AbbVie: Who we are US-ABBV-200135 2

  3. Slide 3: 130+ years of patient care

    AbbVie has as long history in healthcare dating back to 1888 with Abbott 130+ years of patient care Launched as AbbVie in 2013 Millions of lives touched AbbVie: Who we are US-ABBV-200135 3

  4. Slide 4: AbbVie's Mission

    AbbVie’s Mission Create an innovation-driven, patient- focused specialty biopharmaceutical company capable of achieving sustainable top-tier performance through outstanding execution and a consistent stream of innovative new medicines which have a remarkable impact on people’s lives. AbbVie: AbbVie:

  5. Slide 5: With Allergan, AbbVie has an expanded global footprint of state-of-the-art facilities

    With Allergan, AbbVie has an expanded global footprint of state-of-the-art facilities Ireland: Ballytivnan Cork Sligo Ireland: Dublin Michigan, USA Illinois, USA: Galway Wyandotte Lake County Westport North Chicago New Jersey, USA: Branchburg Ludwigshafen, Germany Madison California, USA: Redwood Ci

  6. Slide 6: We have market leadership in attractive growth segments

    We have market leadership in attractive growth segments #1 #2 Immunology Hematologic oncology Leadership in Women’s #1 Aesthetics health #1 Leadership in Eye care Global HCV AbbVie: Who we are US-ABBV-200135 6

  7. Slide 7: Therapeutic areas of focus: Immunology

    Therapeutic areas of focus: Immunology We leverage deep scientific expertise to develop next-generation biologics and small molecules in rheumatology, dermatology and gastroenterology. AbbVie medicines in immunology currently treat +1 million patients in 15 indications worldwide. AbbVie: Who we are

  8. Slide 8: Therapeutic areas of focus: Oncology

    Therapeutic areas of focus: Oncology Current treatment areas: Acute Myeloid Leukemia Chronic Graft vs Host Disease Chronic Lymphocytic Leukemia Mantle Cell Lymphoma Marginal Zone Lymphoma Waldenstrom’s Macroglobulinemia Future areas of focus: Immuno-oncology Apoptosis/B-cell receptor field AbbVie: W

  9. Slide 9: Therapeutic areas of focus: Neuroscience

    Therapeutic areas of focus: Neuroscience We’re researching and developing new, innovative, disease-modifying solutions to address some of the most difficult-to-treat neurodegenerative diseases. Diseases: Additional Indications: • Alzheimer’s disease • Adult Focal Spasticity • Bipolar disorder • Blep

  10. Slide 10: Therapeutic areas of focus: Eye Care

    Therapeutic areas of focus: Eye Care Currently treating: Glaucoma Ocular hypertension Other conditions Researching areas: Retina-related diseases, such as macular edema Diabetic macular edema Age-related macular degeneration AbbVie: Who we are US-ABBV-200135 10

  11. Slide 11: Therapeutic areas of focus: Virology

    Therapeutic areas of focus: Virology We are the global leader in HCV Despite the availability of a cure, most people with HCV are untreated and in the earlier stages of liver disease. Together with the HCV community, AbbVie is a committed member of the global movement towards HCV elimination with th

  12. Slide 12: Other specialties

    Other specialties Focused investments in areas that fit our core strengths include: Cardiology Gastroenterology General medicine Women’s health AbbVie: Who we are US-ABBV-200135 12

  13. Slide 13: #1 leadership position with world-renowned brands

    #1 leadership position with world-renowned brands Current treatments: Body contouring Facial injectables Plastics Regenerative medicine Skin care AbbVie: Who we are US-ABBV-200135 13

  14. Slide 14: Together, we have even greater ability to meet the needs of patients

    Together, we have even greater ability to meet the needs of patients AbbVie Therapeutic Areas Allergan Aesthetics Immunology Oncology Neuroscience Eye Care Virology Women’s Health Other specialty • General medicine Treating across in more than ~60 30+ 175+ conditions brands countries AbbVie: Who we

  15. Slide 15: AbbVie: Who we are US-ABBV-200135

    AbbVie: Who we are US-ABBV-200135 15

  16. Slide 16: AbbVie: Who we are US-ABBV-200135

    AbbVie: Who we are US-ABBV-200135 16

  17. Slide 17: AbbVie's Commitment to Corporate Responsibility

    AbbVie’s Commitment to Corporate Responsibility Corporate strategy: We strive to make a remarkable impact on patients and drive sustainable growth by discovering and delivering a consistent stream of innovative medicines that address serious health problems. Creating real health We recognize that he

  18. Slide 18: #AbbVieGivesBack

    #AbbVieGivesBack: www.abbvie.com/responsibility Employee Giving Global Week of Philanthropic Engaging Children Supporting Volunteerism Giving in STEM Employees During Pivotal Moments AbbVie Foundation Week of Dedicated to making The AbbVie The AEAF provides matches employee Possibilities unites a re

  19. Slide 19: Our commitment to the environment is ongoing

    Our commitment to the environment is ongoing 24% of purchased electricity came from renewable sources 10 New environmental sustainability projects approved through SPARK AbbVie: Who we are US-ABBV-200135 19

  20. Slide 20: External recognition as a top company

    External recognition as a top company Workplace & Diversity Environment, Social Citizenship Business and Governance Performance DiversityInc. “Top 50 Companies for Dow Jones Sustainability World Civic 50 Diversity” Index FORTUNE 100 FORTUNE “100 Best EcoVadis Corporate Social Corporate Responsibilit

  21. Slide 21: Together, we will innovate for tomorrow, while making a remarkable impact for millions today

    Together, we will innovate for tomorrow, while making a remarkable impact for millions today. AbbVie: Who we are US-ABBV-200135 21

  22. Slide 22: People. Passion. Possibilities.

    ® People. Passion. Possibilities. AbbVie: Who we are US-ABBV-200135

AbbVie — Investor Presentation on 6ix